XenoPort to Release Second Quarter Financial Results on August 6, 2014
SANTA CLARA, Calif. -- July 22, 2014
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its second
quarter financial results on August 6, 2014 at approximately 4:30 p.m. Eastern
Time. The company will host a conference call at 5:00 p.m. Eastern Time that
same day. A replay of the call will be available for one week following the
To access the conference call via the Internet, go to www.XenoPort.com. Please
join the call at least 15 minutes prior to the start to ensure time for any
software downloads that may be required.
To access the live conference call via phone, dial 1-888-275-3514.
International callers may access the live call by dialing 706-679-1417. The
reference number to enter the call is 72884596.
The replay of the conference call may be accessed that same day after 8:00
p.m. Eastern Time, via the Internet, at www.XenoPort.com, or via phone at
1-855-859-2056 for domestic callers, or 404-537-3406 for international
callers. The reference number to enter the replay of the call is 72884596.
XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. XenoPort is currently
commercializing HORIZANT^® (gabapentin enacarbil) Extended-Release Tablets in
the United States and developing its novel fumaric acid ester product
candidate, XP23829, as a potential treatment for moderate-to-severe chronic
plaque type psoriasis and/or relapsing forms of multiple sclerosis. REGNITE^®
(gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by
Astellas Pharma Inc. XenoPort recently granted exclusive world-wide rights for
the development and commercialization of its clinical-stage oral product
candidate, arbaclofen placarbil, to Reckitt Benckiser Pharmaceuticals, Inc.
for all indications. To learn more about XenoPort, please visit the website at
XENOPORT, HORIZANT and REGNITE are registered trademarks of XenoPort, Inc.
Jackie Cossmon, 408-616-7295
Press spacebar to pause and continue. Press esc to stop.